Why the study?
Does linezolid dose and trough concentration correlate with mitochondrial toxicity-related adverse events in patients with chronic extensively drug-resistant tuberculosis?
Does linezolid dose and trough concentration correlate with mitochondrial toxicity-related adverse events in patients with chronic extensively drug-resistant tuberculosis?
Therapeutic drug monitoring of linezolid trough concentrations may help prevent mitochondrial toxicity in patients treated for extensively drug-resistant tuberculosis.
Answers are grounded in this paper and cite their sources.
Linezolid 600 mg raises mitochondrial toxicity risk versus 300 mg; supports trough monitoring below 2 μg/ml to guide dosing in XDR-TB.
Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ratio. We compared this ratio with AEs associated with mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600 mg and 300 mg doses. Those on 600 mg had a significantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI 1·23-7 · 86). Mean mitochondrial function levels were significantly higher in patients before starting linezolid compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P < 0·0001). Increasing mean linezolid trough concentrations were associated with lower mitochondrial function levels (Spearman's ρ = - 0.48; P = 0.005). Mitochondrial toxicity risk increased with increasing linezolid trough concentrations, with all patients with mean linezolid trough > 2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg or 600 mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity associated with long-term linezolid use.
No takes yet. Share an insight, caveat, or question.
Song et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: